Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Inflated Drug Prices To Cover Bribery Costs

This article was originally published in PharmAsia News

Executive Summary

A box of lamivudine (Epivir) from GSK sold at RMB 142 ($23.04) in China, but at RMB 18 in South Korea and less than RMB 26 in Canada, according to sources.

A box of lamivudine (Epivir) from GSK sold at RMB 142 ($23.04) in China, but at RMB 18 in South Korea and less than RMB 26 in Canada, according to sources. GSK was alleged by prosecutors to avoid taxes by transferring costs overseas and use the earnings in part to bribe physicians with cash, sponsorship of traveling or academic conferences, and donations. (Click Here For More - Chinese Language)

“Bribery Costs Up To 30% Of Drug Prices; How Outrageous GSK Drug Prices are In China?” - health.people.com.cn (5/15/2014)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC087140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel